The Australia story: Current status and future challenges for the clinical applications of psychedelics

Nutt and colleagues place recent clinical progress with classical psychedelics and MDMA in the context of a large, unmet burden of mental illness and limited effectiveness of existing treatments. They note rapid advances in clinical trials over the past decade (with many agents reaching Phase II and some moving into Phase III), and describe basic pharmacology relevant to clinical action: psilocybin and related 5-HT2A agonists act on cortical layer 5 pyramidal neurons in a way that can disrupt ruminative activity in depression, while MDMA primarily releases serotonin and through 5-HT1A-related mechanisms attenuates fear responses relevant to PTSD. The paper also flags important regulatory milestones, in particular the Australian Therapeutic Goods Administration’s (TGA) decision to approve psilocybin for treatment-resistant depression and MDMA for PTSD to take effect on 1 July 2023, and notes that the article was written before the US FDA’s later rejection of MDMA in June 2024. This paper sets out to explain the background to the TGA decision, to describe how the Australian authorisation framework will work in practice, and to consider implications for other jurisdictions and for the development pathways of other psychedelic drugs. Rather than presenting new trial data, the authors undertake a narrative review and policy analysis of the regulatory process, stakeholder submissions, trial evidence cited by proponents and opponents, and practical delivery models that have been proposed for bringing these medicines into clinical use in Australia.

The extracted text does not present a discrete Methods section describing a systematic search or formal meta-analytic procedure; instead the paper is a narrative review and policy analysis drawing on regulatory documents, stakeholder submissions, public consultation data, and published clinical trial evidence. Key information sources cited or described include the rescheduling applications lodged by the charity Mind Medicine Australia (MMA), the Delegate’s published rationale for initial rejection, subsequent written submissions and public responses to the TGA consultation, and major clinical trials and development programmes referenced by the authors (for example MAPS trials for MDMA and Imperial College trials for psilocybin). Where relevant, the authors incorporate quantitative figures reported in submissions and surveys (for example the number of public submissions and proportions in favour), regulatory timelines (initial applications, interim decisions, resubmissions), and descriptions of proposed clinical protocols. The paper therefore synthesises regulatory and policy material together with selected clinical trial findings rather than applying explicit systematic-review methods; the extracted text does not report search strategies, inclusion criteria, or formal risk-of-bias assessment.

The paper recounts how a coalition led by Mind Medicine Australia and supported by clinicians, researchers and patient groups campaigned for rescheduling of psilocybin and MDMA. The coalition argued that existing treatments often fail: current data cited in the paper suggest about one third of people with depression and roughly 50% of people with PTSD derive no real benefit from pharmacotherapies, with remission rates quoted at about 35% for depression and as low as 10% for PTSD. The authors also emphasise high suicide rates in certain Australian groups (reported for first responders and defence veterans) as part of the rationale for seeking new treatment options. Regulatory and stakeholder dynamics are described in detail. The Royal Australian and New Zealand College of Psychiatrists (RANZCP) opposed rescheduling and its clinical memorandum was criticised by the coalition for lacking transparency, peer review and consultation with international experts; the RANZCP’s position contrasted with its more positive stance on ketamine. MMA lodged an initial set of rescheduling applications that were rejected at interim stages, then refiled in March 2022 with additional data and public support. Public submissions increased markedly between the first and second applications, rising to over 13,000 written submissions with over 98% support for psilocybin and over 95% support for MDMA; among researchers and clinicians only very small absolute numbers were recorded as opposing (for psilocybin 2 out of 92 clinical researchers and no health professionals; for MDMA 1 out of 89 researchers and 2 health professionals, as reported). The paper outlines the Australian clinical model approved under the TGA’s Authorised Prescriber Scheme and the procedural requirements for clinicians. To become an authorised prescriber, a psychiatrist must obtain approval from a Human Research Ethics Committee and from the TGA and must demonstrate appropriate training and protocols. Required protocol elements include (as listed in the extracted text): - the stages of the therapeutic process (diagnosis, contraindications, tapering, informed consent, preparatory, dosing and integration sessions, final review and follow-up); - details of the clinical environment and safety measures for dosing sessions; - the identity, qualifications and training of therapists involved; - medicine details including manufacturer, quality and purity. A practical delivery model (Box 1) is presented: initial medicine supply would be arranged under contract with an overseas GMP manufacturer with distribution handled by an Australian pharmacist; patient selection would be limited to treatment-resistant depression or PTSD (treatment resistance defined as failure of at least two prior treatments, one being an adequate course of a registered medicine); treatment procedures mirror established trial protocols (preparatory session, dosing day, integration session the following day), with psilocybin repeatable once and MDMA up to two additional times at intervals of not less than one month; and a data-collection registry and regular public reporting were envisaged. On safety and harms the authors report that modern clinical and volunteer data involving hundreds of participants show very few reports of significant adverse effects in controlled settings. They also cite four independent studies using multi-criteria decision conferencing that ranked psilocybin and MDMA as low-harm substances compared with many other psychoactive drugs; the authors argue harms are expected to be even lower in medical settings given the small number of therapeutic administrations required. The paper notes logistical considerations — for example that several GMP producers of psilocybin and MDMA exist in Canada and elsewhere — and discusses the potential for non-commercial supply models to increase access in lower-resource settings. Opponents’ concerns, including the risk of self-medication, translation risks for moving a drug into wider medical use, and legal arguments about international conventions, are presented and the coalition’s counter-arguments are summarised.

The authors interpret the TGA decision as being driven by large unmet clinical need, accumulating positive clinical evidence, and strong public and professional support marshalled by the coalition. They contend that the available efficacy and safety data for psilocybin and MDMA are at least comparable to that for ketamine (a medicine already used off-licence in psychiatry), and that rescheduling under the Authorised Prescriber Scheme provides a regulated pathway to deliver treatments while collecting real-world evidence to inform ongoing practice. In positioning these findings relative to earlier research and practice, the paper argues that many negative perceptions of psychedelics are overstated when contemporary clinical data and historical medical use are taken into account. The authors emphasise that the risks can be mitigated through mandated training, clinical protocols and governance, and that supply challenges are solvable via existing GMP manufacturers and distribution arrangements. They also highlight broader implications: other jurisdictions may follow the Australian model or adapt it, and countries with limited resources might rely on non-commercial provision if market-priced products prove unaffordable. Key limitations and uncertainties acknowledged in the extracted text include ongoing debate among professional bodies (for example the RANZCP’s concerns regarding transparency and consultation), potential translation risks in scaling up use beyond trial settings, and the possibility that new chemical entities without historical clinical experience would not be able to follow the same regulatory route. The authors note the need for continued real-world monitoring and data publication from registries. Finally, they flag that the regulatory and commercial landscape remains dynamic — in particular they note this paper was prepared before the FDA’s subsequent decision on MDMA — and that future approvals, company strategies and further trial results will shape how these medicines are adopted internationally.